Nefazodone undergoes extensive first-pass metabolism, resulting in bioavailability of only 15 – 23%. As is usually the case, first-pass metabolism becomes saturated with chronic dosing, resulting in greater elevations of plasma concentration with dosage increases later in treatment.
Ref: - Dubovsky, S.L. & Thomas, M. (1995) Serotonergic mechanisms and current and future psychiatric practice. Journal of Clinical Psychiatry, 56 (suppl 2): 38-48.
No Pingbacks for this post yet...
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
| << < | > >> | |||||
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |
This blog on Clinical Psychopharmacology is maintained by Dr. Shahul Ameen, M.D., Psychiatrist, St. John's Hospital, Kattappana, Idukki, Kerala, India.
Psychopharmacology Tips is a part of PsyPlexus, a portal for mental health professionals.
This blog is only for educational purpose of psychiatrists and other physicians. The information published in this blog is not intended for use as a substitute for consultation to a licensed health professional. Patients and consumers who visit Psychopharmacology Tips should carefully review the information gathered from the site with a professional healthcare provider.